Early clinical trial data are generating cautious optimism in the oncology community as high-dose vitamin B3 (niacin) demonstrates the ability to restore immune function against glioblastoma, one of the brain’s most aggressive malignancies. Researchers report that niacin supplementation reactivates exhausted T-cells by restoring NAD+ metabolism—a critical pathway that tumours typically exploit to evade immune detection. Trial participants receiving the intervention showed progression-free survival rates that exceeded historical benchmarks for standard glioblastoma care. While these preliminary findings are encouraging, the research team emphasises that further validation through larger multicentre trials is essential before clinical implementation. The mechanism of action—targeting immune exhaustion rather than the tumour directly—represents a novel therapeutic paradigm for this devastating disease. Read the full article on GMJ Newsroom.
Was this article helpful?
